Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by ARK Investment Management LLC

ARK Investment Management LLC lowered its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 8.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,933,851 shares of the biotechnology company’s stock after selling 167,187 shares during the quarter. ARK Investment Management LLC owned approximately 0.07% of Arcturus Therapeutics worth $32,817,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Empire Life Investments Inc. grew its stake in shares of Arcturus Therapeutics by 85.5% in the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock worth $4,742,000 after purchasing an additional 128,771 shares during the last quarter. Spire Wealth Management grew its stake in shares of Arcturus Therapeutics by 393.3% in the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 10,746 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Arcturus Therapeutics by 45.0% in the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 3,705 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Arcturus Therapeutics by 139.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock worth $1,393,000 after buying an additional 47,824 shares during the period. Finally, Nordea Investment Management AB boosted its holdings in shares of Arcturus Therapeutics by 3.7% in the fourth quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock worth $1,097,000 after buying an additional 2,335 shares during the period. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Performance

ARCT stock opened at $16.06 on Wednesday. The stock has a market cap of $435.07 million, a P/E ratio of -7.23 and a beta of 2.62. The firm has a 50 day simple moving average of $16.98 and a 200 day simple moving average of $18.81. Arcturus Therapeutics Holdings Inc. has a 52 week low of $14.30 and a 52 week high of $45.00.

Analysts Set New Price Targets

Several research analysts have commented on ARCT shares. HC Wainwright reiterated a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a report on Friday, February 14th. BTIG Research started coverage on shares of Arcturus Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $41.00 target price for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Arcturus Therapeutics presently has a consensus rating of “Buy” and an average target price of $65.00.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.